What question did this study set out to answer?

Evaluate efficacy and outcomes of etoposide plus G-CSF in stem cell mobilization for multiple myeloma patients treated with daratumumab.

December 8, 2025Blood

Etoposide +cytarabine plus G-CSF mitigates daratumumab-associated impairment on stem cell mobilization yields in multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows impaired stem cell mobilization in multiple myeloma with daratumumab, suggesting etoposide and G-CSF improve outcomes.

Evaluate efficacy and outcomes of etoposide plus G-CSF in stem cell mobilization for multiple myeloma patients treated with daratumumab.
Single-center retrospective analysis
Enrolled 105 MM patients with dara-based (n=37) or lena-based (n=68) induction therapy
Mobilization regimen: etoposide + cytarabine (EA) plus G-CSF for apheresis.
Median CD34+ cell collection lower in dara group (19.33×10⁶/kg) versus lena group (25.59×10⁶/kg, p=0.005)
89.2% of patients in dara group achieved at least 10×10⁶ CD34+ cells/kg for tandem ASCT
45.9% of dara patients required two-day apheresis compared to 17.6% in lena group (p=0.002)

Xiaofan Li (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis shows impaired stem cell mobilization in multiple myeloma with daratumumab, suggesting etoposide and G-CSF improve outcomes.